Financial Performance - Porch Group, Inc. reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.13, compared to a loss of $0.65 per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $107.02 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 10.83%, although this is a decrease from year-ago revenues of $110.84 million [2] - Over the last four quarters, Porch Group has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Porch Group shares have increased approximately 161.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $110.36 million, and for the current fiscal year, it is -$0.18 on revenues of $405.86 million [7] Industry Outlook - The Internet - Software industry, to which Porch Group belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the stock's performance may be influenced by these revisions [5][6]

Company Performance - LifeMD, Inc. reported a quarterly loss of $0.06 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.02, representing an earnings surprise of -200.00% [1] - The company posted revenues of $62.22 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 6.02%, but showing an increase from $50.66 million in the same quarter last year [2] - Over the last four quarters, LifeMD has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - LifeMD shares have increased approximately 149.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $67.5 million, and for the current fiscal year, it is $0.04 on revenues of $268.15 million [7] Industry Outlook - The Medical Services industry, to which LifeMD belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact LifeMD's stock performance [5]

Core Viewpoint - Revolve Group (RVLV) reported quarterly earnings of $0.14 per share, exceeding the Zacks Consensus Estimate of $0.12 per share, but down from $0.21 per share a year ago, indicating a +16.67% earnings surprise [1] Financial Performance - The company achieved revenues of $308.97 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.36% and up from $282.46 million year-over-year [2] - Over the last four quarters, Revolve Group has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance - Revolve Group shares have declined approximately 39.1% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $294.07 million, and for the current fiscal year, it is $0.41 on revenues of $1.19 billion [7] - The estimate revisions trend for Revolve Group was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Textile - Apparel industry, to which Revolve Group belongs, is currently ranked in the bottom 19% of over 250 Zacks industries, suggesting potential challenges ahead [8] - G-III Apparel Group, another company in the same industry, is expected to report a significant decline in earnings, with a consensus EPS estimate of $0.10, reflecting a year-over-year change of -80.8% [9]

Company Performance - A10 Networks reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.20 per share, and up from $0.18 per share a year ago, representing an earnings surprise of +5.00% [1] - The company achieved revenues of $69.38 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.30%, compared to $60.1 million in the same quarter last year [2] - Over the last four quarters, A10 Networks has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Market Outlook - A10 Networks shares have underperformed the market, losing about 1.3% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the coming quarter is $0.22 on revenues of $70.2 million, and for the current fiscal year, it is $0.87 on revenues of $279.71 million [7] Industry Context - The Communication - Network Software industry, to which A10 Networks belongs, is currently ranked in the bottom 27% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Company Performance - OrthoPediatrics reported a quarterly loss of $0.11 per share, better than the Zacks Consensus Estimate of a loss of $0.17, and an improvement from a loss of $0.23 per share a year ago, resulting in an earnings surprise of +35.29% [1] - The company posted revenues of $61.08 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1%, but showing an increase from year-ago revenues of $52.8 million [2] - Over the last four quarters, OrthoPediatrics has surpassed consensus EPS estimates just once and topped consensus revenue estimates two times [2] Stock Outlook - OrthoPediatrics shares have declined approximately 11.4% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The company's earnings outlook is mixed, with the current consensus EPS estimate for the coming quarter at -$0.14 on revenues of $63.72 million, and -$1.24 on revenues of $239.45 million for the current fiscal year [7] Industry Context - The Medical - Instruments industry, to which OrthoPediatrics belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact OrthoPediatrics' stock performance [5]

Group 1: Earnings Performance - Super Micro Computer (SMCI) reported quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.44 per share, and down from $0.63 per share a year ago, representing an earnings surprise of -6.82% [1] - The company posted revenues of $5.76 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 3.82%, compared to year-ago revenues of $5.31 billion [2] - Over the last four quarters, Super Micro has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Group 2: Stock Performance and Outlook - Super Micro shares have increased approximately 91% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $0.56 on $6.61 billion in revenues for the coming quarter and $2.51 on $29.63 billion in revenues for the current fiscal year [7] Group 3: Industry Context - The Computer-Storage Devices industry, to which Super Micro belongs, is currently ranked in the top 21% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Another company in the same industry, Quantum Corp. (QMCO), is expected to report a quarterly loss of $0.15 per share, reflecting a year-over-year change of +91.7%, with revenues projected at $73.7 million, up 3.3% from the previous year [9]

Company Performance - ViaSat reported quarterly earnings of $0.17 per share, exceeding the Zacks Consensus Estimate of a loss of $0.05 per share, and improved from a loss of $0.26 per share a year ago [1] - The earnings surprise was +440.00%, contrasting with a previous quarter where a loss of $0.02 was reported against an expectation of $0.03, resulting in a surprise of -166.67% [2] - Revenues for the quarter ended June 2025 were $1.17 billion, surpassing the Zacks Consensus Estimate by 3.71%, and up from $1.13 billion year-over-year [3] Stock Performance - ViaSat shares have increased approximately 138.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [4] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $1.15 billion, and for the current fiscal year, it is $0.06 on revenues of $4.64 billion [8] Industry Outlook - The Wireless Equipment industry, to which ViaSat belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, indicating potential challenges ahead [9] - Ubiquiti Inc., another company in the same industry, is expected to report quarterly earnings of $1.94 per share, reflecting a year-over-year change of +11.5%, with revenues anticipated to be $615.07 million, up 21.2% from the previous year [10]

Core Viewpoint - Powell Industries reported quarterly earnings of $3.96 per share, exceeding the Zacks Consensus Estimate of $3.73 per share, and showing an earnings surprise of +6.17% [1] - The company posted revenues of $286.27 million for the quarter, missing the Zacks Consensus Estimate by 3% [2] Financial Performance - Earnings per share (EPS) for the same quarter last year was $3.79, indicating a year-over-year increase [1] - Over the last four quarters, Powell Industries has surpassed consensus EPS estimates four times [2] - The company has topped consensus revenue estimates only once in the last four quarters [2] Stock Performance - Powell Industries shares have increased by approximately 3.8% since the beginning of the year, compared to the S&P 500's gain of 7.6% [3] - The current Zacks Rank for Powell Industries is 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $3.77, with expected revenues of $296.61 million [7] - For the current fiscal year, the consensus EPS estimate is $14.17 on revenues of $1.11 billion [7] - The outlook for the Manufacturing - Electronics industry is strong, currently ranking in the top 25% of over 250 Zacks industries [8]

Financial Performance - BridgeBio Pharma reported a quarterly loss of $0.95 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.83, representing an earnings surprise of -14.46% [1] - The company posted revenues of $110.57 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 14.95%, compared to revenues of $2.17 million a year ago [2] - Over the last four quarters, BridgeBio Pharma has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - BridgeBio Pharma shares have increased approximately 74% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.61 on revenues of $136.32 million, and for the current fiscal year, it is -$3.16 on revenues of $466.56 million [7] - The estimate revisions trend for BridgeBio Pharma was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Generic Drugs industry, to which BridgeBio Pharma belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Viewpoint - DaVita HealthCare reported quarterly earnings of $2.95 per share, exceeding the Zacks Consensus Estimate of $2.7 per share, and showing an increase from $2.59 per share a year ago, indicating a positive earnings surprise of +9.26% [1][2] Financial Performance - The company achieved revenues of $3.38 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.31% and up from $3.19 billion year-over-year [2] - Over the last four quarters, DaVita has exceeded consensus EPS estimates three times and topped revenue estimates four times [2] Stock Performance - DaVita HealthCare shares have declined approximately 6.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $3.21 on revenues of $3.42 billion, and for the current fiscal year, it is $10.76 on revenues of $13.48 billion [7] - The outlook for the Medical - Outpatient and Home Healthcare industry is positive, ranking in the top 27% of over 250 Zacks industries, suggesting potential for outperformance [8]